Kanteron Systems USA taps Merge's Memarian for president, chief commercial officer

Kanteron Systems USA announced this week that John Memarian will be joining the workflow management company as president and chief commercial officer. Memarian is currently the president of international businesses at Merge Healthcare, which was acquired by IBM last year for $1 billion.

Memarian officially joins Kanteron on March 1. His responsibilities will include the company’s commercial strategy, business development, and more.

“I am thrilled that John will be joining our team,” Kanteron founder and CEO Jorge Cortell said in a prepared statement. “He shares our values and our focus on innovation, and he places the same strong emphasis as we do on customer satisfaction. He has shown himself to be an extraordinary leader throughout his career and has a proven track record.”

Memarian said in the same statement he is excited about this new opportunity.

“I am profoundly honored to join Kanteron in this newly created position, and very much look forward to working with such an amazing team of innovators,” Memarian said. “I am completely convinced of the impact Kanteron products and services can have on the healthcare industry around personalized medicine and look forward to contributing to the company’s continued success and leadership in changing the healthcare world.”

 
Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.